Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL L LEONARDI

Allopathic & Osteopathic Physicians Pediatrics

NPI
1932295425
CMS profile
418556
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$53.38

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.38 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
NeurAxis, Inc. $53.38 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL L LEONARDI

NPI 1932295425 · CMS profile ID 418556

Allopathic & Osteopathic Physicians / Pediatrics

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932295425?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932295425?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932295425?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1932295425?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NeurAxis, Inc. $53.3803/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120672014 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25.81 3
PY2020 $888.89 2
PY2021 $18.05 1
PY2024 $53.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $55,396.18 17
PY2024 Principal investigator $110,737.73 24
PY2023 Principal investigator $174,788.60 91
PY2022 Principal investigator $755,230.68 69
PY2021 Principal investigator $485,798.70 79
PY2020 Principal investigator $231,870.31 96
PY2019 Principal investigator $225,139.83 126

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,785.20 12/31/2019 Non-covered Recipient Entity
Palmetto Pediatrics
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 684987819
Principal investigator 1 AstraZeneca Pharmaceuticals LP $92.93 12/31/2019 Non-covered Recipient Entity
Palmetto Pediatrics
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684987823
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 12/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691470967
Principal investigator 1 GlaxoSmithKline, LLC. $1,784.70 12/20/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669968251
Principal investigator 1 Merck Sharp & Dohme Corporation $11,154.60 12/19/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691470963
Principal investigator 1 Merck Sharp & Dohme Corporation $46.02 12/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691512277
Principal investigator 1 Merck Sharp & Dohme Corporation $579.51 12/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691513043
Principal investigator 1 Merck Sharp & Dohme Corporation $80.75 12/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691513045
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 12/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691514028
Principal investigator 1 GlaxoSmithKline, LLC. $2,369.70 12/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967441
Principal investigator 1 GlaxoSmithKline, LLC. $1,360.80 12/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669969463
Principal investigator 1 GlaxoSmithKline, LLC. $1,749.60 12/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669970043
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.70 12/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669976029
Principal investigator 1 PFIZER INC. $423.46 11/28/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671669617
Principal investigator 1 Merck Sharp & Dohme Corporation $11,571.60 11/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691430577
Principal investigator 1 Merck Sharp & Dohme Corporation $264.15 11/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691496193
Principal investigator 1 Merck Sharp & Dohme Corporation $264.15 11/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691501739
Principal investigator 1 Merck Sharp & Dohme Corporation $11,756.40 10/29/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449917
Principal investigator 1 GlaxoSmithKline, LLC. $1,650.60 10/23/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669966893
Principal investigator 1 PFIZER INC. $211.73 10/23/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671676427
Principal investigator 1 Merck Sharp & Dohme Corporation $9,837.00 10/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449919
Principal investigator 1 Merck Sharp & Dohme Corporation $579.51 10/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691511277
Principal investigator 1 Merck Sharp & Dohme Corporation $145.35 10/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691511955
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 10/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691513047
Principal investigator 1 Merck Sharp & Dohme Corporation $974.79 10/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691513051
Principal investigator 1 GlaxoSmithKline, LLC. $1,024.20 10/16/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669968765
Principal investigator 1 Merck Sharp & Dohme Corporation $193.71 10/15/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691390875
Principal investigator 1 Merck Sharp & Dohme Corporation $193.71 10/15/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691501737
Principal investigator 1 GlaxoSmithKline, LLC. $2,334.60 10/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669975755
Principal investigator 1 GlaxoSmithKline, LLC. $1,537.20 10/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669976397
Principal investigator 1 GlaxoSmithKline, LLC. $1,118.70 10/02/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669963935
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.70 10/02/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669966891
Principal investigator 1 GlaxoSmithKline, LLC. $1,412.10 09/30/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669962299
Principal investigator 1 GlaxoSmithKline, LLC. $1,071.00 09/30/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964805
Principal investigator 1 GlaxoSmithKline, LLC. $5,153.40 09/30/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
ROTA-090 No dispute reported 06/30/2026 669973455
Principal investigator 1 Merck Sharp & Dohme Corporation $223.20 09/25/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691511961
Principal investigator 1 PFIZER INC. $847.54 09/25/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671679281
Principal investigator 1 GlaxoSmithKline, LLC. $1,744.20 09/18/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669973453
Principal investigator 1 GlaxoSmithKline, LLC. $1,475.10 09/11/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669973451
Principal investigator 1 Merck Sharp & Dohme Corporation $1,191.41 09/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449923
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 09/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449955
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 09/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449999
Principal investigator 1 Merck Sharp & Dohme Corporation $177.65 09/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691450003
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,948.60 09/05/2019 Non-covered Recipient Entity
Palmetto Pediatrics
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 684987807
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/29/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691353065
Principal investigator 1 GlaxoSmithKline, LLC. $1,190.70 08/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964385
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 08/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691359985
Principal investigator 1 GlaxoSmithKline, LLC. $2,395.80 08/21/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964103
Principal investigator 1 PFIZER INC. $848.16 08/21/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671675571
Principal investigator 1 Merck Sharp & Dohme Corporation $5,417.60 08/20/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691360245
Principal investigator 1 GlaxoSmithKline, LLC. $1,030.50 08/13/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669966465
Principal investigator 1 Merck Sharp & Dohme Corporation $74.40 08/09/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691478113
Principal investigator 1 Merck Sharp & Dohme Corporation $80.75 08/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449949
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 08/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449995
Principal investigator 1 Merck Sharp & Dohme Corporation $974.79 08/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451687
Principal investigator 1 Merck Sharp & Dohme Corporation $61.36 08/08/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451703
Principal investigator 1 GlaxoSmithKline, LLC. $1,454.40 08/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964099
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 08/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964101
Principal investigator 1 GlaxoSmithKline, LLC. $1,692.00 08/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669975093
Principal investigator 1 Merck Sharp & Dohme Corporation $386.34 07/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451605
Principal investigator 1 Merck Sharp & Dohme Corporation $433.24 07/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451693
Principal investigator 1 Merck Sharp & Dohme Corporation $64.60 07/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451709
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 07/27/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691452849
Principal investigator 1 GlaxoSmithKline, LLC. $5,473.00 07/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
ROTA-081 No dispute reported 06/30/2026 669964279
Principal investigator 1 GlaxoSmithKline, LLC. $1,116.90 07/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669966463
Principal investigator 1 Merck Sharp & Dohme Corporation $197.00 07/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691342805
Principal investigator 1 PFIZER INC. $2,508.96 07/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671635193
Principal investigator 1 Merck Sharp & Dohme Corporation $2,579.78 07/18/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691353875
Principal investigator 1 Merck Sharp & Dohme Corporation $148.80 07/18/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691471995
Principal investigator 1 GlaxoSmithKline, LLC. $1,071.00 07/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669968827
Principal investigator 1 GlaxoSmithKline, LLC. $1,530.90 07/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964357
Principal investigator 1 Merck Sharp & Dohme Corporation $64.60 07/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691450699
Principal investigator 1 Merck Sharp & Dohme Corporation $30.68 07/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451275
Principal investigator 1 Merck Sharp & Dohme Corporation $386.34 07/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451609
Principal investigator 1 Merck Sharp & Dohme Corporation $433.24 07/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691453615
Principal investigator 1 GlaxoSmithKline, LLC. $1,697.40 06/26/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964097
Principal investigator 1 PFIZER INC. $1,543.12 06/26/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671635191
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 06/25/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691359977
Principal investigator 1 GlaxoSmithKline, LLC. $1,231.70 06/19/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669963981
Principal investigator 1 GlaxoSmithKline, LLC. $15.17 06/19/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669966407
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.80 06/12/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669963979
Principal investigator 1 GlaxoSmithKline, LLC. $1,991.70 06/12/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669973449
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.80 06/12/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669975091
Principal investigator 1 Merck Sharp & Dohme Corporation $76.70 06/11/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449943
Principal investigator 1 Merck Sharp & Dohme Corporation $80.75 06/11/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449945
Principal investigator 1 Merck Sharp & Dohme Corporation $965.85 06/11/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451683
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 06/11/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691451699
Principal investigator 1 Merck Sharp & Dohme Corporation $19.40 06/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691342173
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 06/06/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691487263
Principal investigator 1 Merck Sharp & Dohme Corporation $149.70 05/29/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691360249
Principal investigator 1 Merck Sharp & Dohme Corporation $386.10 05/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691359003
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 05/23/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691359973
Principal investigator 1 GlaxoSmithKline, LLC. $1,722.60 05/22/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957331
Principal investigator 1 GlaxoSmithKline, LLC. $1,024.20 05/22/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669972403
Principal investigator 1 PFIZER INC. $1,389.92 05/22/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671644783
Principal investigator 1 GlaxoSmithKline, LLC. $2,070.00 05/15/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669971821
Principal investigator 1 PFIZER INC. $1,408.00 05/15/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671644839
Principal investigator 1 PFIZER INC. $3,553.00 05/15/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671644841
Principal investigator 1 Merck Sharp & Dohme Corporation $342.00 05/07/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691359981
Principal investigator 1 Merck Sharp & Dohme Corporation $3,000.00 05/02/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691359989
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/02/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691360243
Principal investigator 1 GlaxoSmithKline, LLC. $1,116.90 04/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957691
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 04/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669972665
Principal investigator 1 PFIZER INC. $848.16 04/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671644781
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.70 04/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669956851
Principal investigator 1 GlaxoSmithKline, LLC. $1,071.90 04/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669956921
Principal investigator 1 GlaxoSmithKline, LLC. $2,349.00 04/10/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957093
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.70 04/03/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669962259
Principal investigator 1 GlaxoSmithKline, LLC. $2,152.80 03/25/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957329
Principal investigator 1 GlaxoSmithKline, LLC. $3,477.60 03/25/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957689
Principal investigator 1 Merck Sharp & Dohme Corporation $1,026.00 03/19/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691318973
Principal investigator 1 GlaxoSmithKline, LLC. $3,326.40 03/14/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669956919
Principal investigator 1 GlaxoSmithKline, LLC. $1,604.70 03/14/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669971819
Principal investigator 1 PFIZER INC. $1,814.00 03/13/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671632851
Principal investigator 1 Merck Sharp & Dohme Corporation $1,026.00 02/28/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691326607
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.80 02/21/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953663
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,090.50 02/14/2019 Non-covered Recipient Entity
Palmetto Pediatrics
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684987813
Principal investigator 1 PFIZER INC. $1,046.81 02/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671617679
Principal investigator 1 PFIZER INC. $1,258.54 02/04/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671617711
Principal investigator 1 GlaxoSmithKline, LLC. $2,039.40 02/01/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953425
Principal investigator 1 GlaxoSmithKline, LLC. $1,635.30 02/01/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953427
Principal investigator 1 Merck Sharp & Dohme Corporation $1,026.00 01/29/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691308473
Principal investigator 1 Merck Sharp & Dohme Corporation $68.50 01/29/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691342811
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.80 01/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953457
Principal investigator 1 GlaxoSmithKline, LLC. $1,604.70 01/24/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953505
Principal investigator 1 Merck Sharp & Dohme Corporation $938.40 01/17/2019 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691308477